Novel Use of Endogenous GH-Measurement Directly after Transsphenoidal Microsurgery in Acromegaly Treated with Pegvisomant

Abstract

Objective:

The GH receptor antagonist pegvisomant is increasingly used as therapy in acromegaly. Pituitary surgery might be indicated on pegvisomant treatment, due to side effects, adenoma growth or intention to cure after primary treatment. This study was initiated to clarify if, and when, GH measurement could be useful postoperatively with an assay specific for endogenous GH that does not cross-react with pegvisomant.

Methods:

This study was designed as a prospective study in 2006 with the German Pituitary Working Group. Only 2 cases with potentially resectable adenomas from the German Pegvisomant Observational Study (GPOS) had been operated. Now with a post-operative follow-up of more than 5 years in these 2 cases, the usefulness of immediate pre-operative GH measurement shortly after pegvisomant treatment was evaluated.

Results:

In both patients a steep decline of endogenous GH after transnasal microsurgery could be proven by using the special GH assay after near radical or radical removal, of the GH secreting adenomas respectively. Conventional GH assays showed no effect. GH half-life was more than 20 min in the patient with a small invasive residual adenoma and less than 20 min in the cured patient. Endogenous GH-levels declined to less than 1 ng/ml in the days after surgery in the patient with long-term cure.

Conclusion:

Measurement of endogenous GH in this special subgroup of patients under pegvisomant therapy can be used to decide upon early reoperation. Thus the beneficial effect of pegvisomant on acromegalic symptoms can be kept without interfering with post-operative monitoring of GH levels.

Key words

acromegaly - pegvisomant - endogenous GH - transsphenoidal surgery

• References

• 1 Ludecke DK, Abe T. Transsphenoidal microsurgery for newly diagnosed acromegaly: a personal view after more than 1 000 operations. Neuroendocrinology [Review] 2006; 83: 230-239
• 2 Colao A, Pivonello R, Auriemma RS et al. Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance. Eur J Endocrinol [Research Support, Non-U.S. Gov’t] 2006; 154: 467-477
• 3 Strasburger CJ, Buchfelder M, Droste M et al. Experience from the German pegvisomant observational study. Horm Res 2007; 68: 70-73
• 4 Giustina A, Bronstein MD, Casanueva FF et al. Current management practices for acromegaly: an international survey. Pituitary [Evaluation Studies Multicenter Study]. 2011 14. 125-133
• 5 van der Lely AJ, Muller A, Janssen JA et al. Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient. J Clin Endocrinol Metab [Case Reports] 2001; 86: 478-481
• 6 Buhk JH, Jung S, Psychogios MN et al. Tumor volume of growth hormone-secreting pituitary adenomas during treatment with pegvisomant: a prospective multicenter study. J Clin Endocrinol Metab [Clinical Trial Multicenter Study Research Support, Non-U.S. Gov’t] 2010; 95: 552-558
• 7 Ludecke DK. Recent developments in the treatment of acromegaly. Neurosurg Rev 1985; 8: 167-173
• 8 Buchfelder M, Weigel D, Droste M et al. Pituitary tumor size in acromegaly during pegvisomant treatment: experience from MR re-evaluations of the German Pegvisomant Observational Study. Eur J Endocrinol [Multicenter Study Research Support, Non-U.S. Gov’t] 2009; 161: 27-35
• 9 Lüdecke D. Improvement of Microsurgery by Immediate Postoperative Hormone Measurements – Example Acromegaly. Act Endoc Stoffw 1984; 5: 57-61
• 10 Thorner MO, Strasburger CJ, Wu Z et al. Growth hormone (GH) receptor blockade with a PEG-modified GH (B2036-PEG) lowers serum insulin-like growth factor-I but does not acutely stimulate serum GH. J Clin Endocrinol Metab [Clinical Trial Clinical Trial, Phase I Research Support, U.S. Gov’t, Non-P.H.S. Research Support, U.S. Gov’t, P.H.S.] 1999; 84: 2098-2103
• 11 Yamada S, Shishiba Y, Kitano M et al. Decrease in human growth hormone (HGH) levels during transsphenoidal surgery for acromegaly as a guide for prognosis. Endocrinol Jpn 1985; 32: 899-906
• 12 Fahlbusch R, Keller B, Ganslandt O et al. Transsphenoidal surgery in acromegaly investigated by intraoperative high-field magnetic resonance imaging. Eur J Endocrinol [Clinical Trial Research Support, Non-U.S. Gov’t] 2005; 153: 239-248
• 13 Swearingen B. Update on pituitary surgery. J Clin Endocrinol Metab [Comparative Study Review] 2012; 97: 1073-1081
• 14 Schatz H, Stracke H, Zapf J. Insulin-like growth factor IGF-1/somatomedin C as indicator of activity in acromegaly. In: Lüdecke DK, Tolis G. eds. Growth hormone, Growth factors, and Acromegaly. New York, NY: Raven Press; 1987: 85-93
• 15 Manolopoulou J, Alami Y, Petersenn S et al. Automated 22-kD Growth Hormone-Specific Assay without Interference from Pegvisomant. Clin Chem 2012; 58: 1446-1456
• 16 Wang YY, Higham C, Kearney T et al. Acromegaly surgery in Manchester revisited – the impact of reducing surgeon numbers and the 2010 consensus guidelines for disease remission. Clin Endocrinol (Oxf) [Research Support, Non-U.S. Gov’t]. 2012 76. 399-406